Company Overview: Moleculin Biotech

About the Company

Moleculin Biotech
Facebook

Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center, the world’s largest cancer research facility headquartered within the world’s largest medical center. Each of our projects represents a breakthrough discovery and a highly disruptive technology.

Our lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML.

Unlike current therapies that risk cardiotoxicity and can have their effectiveness limited due to multidrug resistance, Annamycin appears capable of avoiding both of these problems and has already demonstrated the ability to save lives in clinic.  We are now preparing to seek accelerated approval for this game-changing drug.

We also have two active pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target cell signaling mechanisms and appears capable stimulating the patient’s natural immune system while also attacking tumors directly.  The other portfolio targets the metabolism of tumors and exploits a unique approach for crossing the blood brain barrier for the treatment of glioblastoma and other central nervous system malignancies.


Investor Toolkit

Company News

  • Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia

    HOUSTON, TX–(Marketwired – March 22, 2017) – Moleculin Biotech, Inc., (MBRX) (“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of...

  • Moleculin to Present at the 29th Annual Roth Capital Conference

    HOUSTON, TX–(Marketwired – March 10, 2017) – Moleculin Biotech, Inc., (MBRX) (“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of...

  • Moleculin Announces Pricing of $5 Million Underwritten Public Offering

    HOUSTON, TX–(Marketwired – February 09, 2017) – Moleculin Biotech, Inc., (MBRX) (“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on license agreements with The University of...

  • Moleculin Announces Expanded Scientific Advisory Board

    HOUSTON, TX–(Marketwired – January 19, 2017) – Moleculin Biotech, Inc., (MBRX) (“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on license agreements with The University of...

Email Subscription

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address